Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Net Income towards Common Stockholders (2020 - 2023)

Historic Net Income towards Common Stockholders for Therapeutics (RAPT) over the last 4 years, with Q4 2023 value amounting to -$33.2 million.

  • Therapeutics' Net Income towards Common Stockholders fell 3596.25% to -$33.2 million in Q4 2023 from the same period last year, while for Sep 2024 it was -$33.2 million, marking a year-over-year increase of 7191.57%. This contributed to the annual value of -$127.1 million for FY2023, which is 4809.95% down from last year.
  • As of Q4 2023, Therapeutics' Net Income towards Common Stockholders stood at -$33.2 million, which was down 3596.25% from -$33.9 million recorded in Q3 2023.
  • Over the past 5 years, Therapeutics' Net Income towards Common Stockholders peaked at -$12.4 million during Q2 2020, and registered a low of -$33.9 million during Q3 2023.
  • Moreover, its 4-year median value for Net Income towards Common Stockholders was -$18.8 million (2021), whereas its average is -$20.9 million.
  • Per our database at Business Quant, Therapeutics' Net Income towards Common Stockholders crashed by 1622.97% in 2022 and then plummeted by 5646.74% in 2023.
  • Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$12.7 million in 2020, then crashed by 40.79% to -$17.9 million in 2021, then plummeted by 36.27% to -$24.4 million in 2022, then tumbled by 35.96% to -$33.2 million in 2023.
  • Its Net Income towards Common Stockholders stands at -$33.2 million for Q4 2023, versus -$33.9 million for Q3 2023 and -$28.4 million for Q2 2023.